Rizzieri D - Search Results

1

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Kantarjian HM, et al. Among authors: rizzieri d. Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24. Lancet Oncol. 2017. PMID: 28844816 Free PMC article. Clinical Trial.

2

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO. Rizzieri DA, et al. J Clin Oncol. 2002 Feb 1;20(3):674-9. doi: 10.1200/JCO.2002.20.3.674. J Clin Oncol. 2002. PMID: 11821447 Clinical Trial.

3

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA. Bass AJ, et al. J Clin Oncol. 2002 Jul 1;20(13):2995-3000. doi: 10.1200/JCO.2002.08.166. J Clin Oncol. 2002. PMID: 12089230 Clinical Trial.

4

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Schiller GJ, et al. Among authors: rizzieri d. J Clin Oncol. 2006 Jun 1;24(16):2456-64. doi: 10.1200/JCO.2005.03.7903. Epub 2006 May 1. J Clin Oncol. 2006. PMID: 16651647 Clinical Trial.

5

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S. Giles F, et al. Among authors: rizzieri d. J Clin Oncol. 2007 Jan 1;25(1):25-31. doi: 10.1200/JCO.2006.07.0961. Epub 2006 Dec 4. J Clin Oncol. 2007. PMID: 17146105 Clinical Trial.

6

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.

Frankel A, Liu JS, Rizzieri D, Hogge D. Frankel A, et al. Among authors: rizzieri d. Leuk Lymphoma. 2008 Mar;49(3):543-53. doi: 10.1080/10428190701799035. Leuk Lymphoma. 2008. PMID: 18297533 Clinical Trial.

7

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. Rizzieri DA, et al. Clin Cancer Res. 2008 May 1;14(9):2756-62. doi: 10.1158/1078-0432.CCR-07-1372. Clin Cancer Res. 2008. PMID: 18451242 Clinical Trial.

8

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B. Rao AV, et al. J Clin Oncol. 2009 Nov 20;27(33):5580-6. doi: 10.1200/JCO.2009.22.2547. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858393

9

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S. Giles F, et al. Among authors: rizzieri d. Leuk Res. 2012 Apr;36(4):e71-3. doi: 10.1016/j.leukres.2011.12.010. Epub 2012 Jan 9. Leuk Res. 2012. PMID: 22226018 Free PMC article. Clinical Trial. No abstract available.

10

Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria.

Rizzieri DA, Walsh K. Rizzieri DA, et al. Clin Adv Hematol Oncol. 2012 Feb;10(2):136-7. Clin Adv Hematol Oncol. 2012. PMID: 22402360 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters